

1 **TITLE: A Randomized, Double-blind, Placebo-controlled Crossover Pilot Study of the Effect**
2 **of Metformin on Airway Glucose in COPD: The Metformin and Airway Glucose In COPD**
3 **(MAGIC) Trial**

4
5 **Authors' full names:** Eva Fiorenzo¹, * John S. Tregoning²,* Isaac Fahidi¹, Michael R. Edwards¹,
6 Tata Keadze¹, Patrick Mallia¹, Sebastian L. Johnston¹, Hugo A. Farne¹.

7
8 **Authors' affiliation(s):**

9
10 ¹ **National Heart and Lung Institute, Imperial College London**

11 ² **Department of Infectious Disease, Imperial College London**

12 * Contributed equally.

13
14 **Corresponding author details:**

15 Name: Hugo Farne

16 Email: h.farne@imperial.ac.uk

17 Twitter account name (optional): @HugoResp

18
19 **ClinicalTrials.gov Identifier:** NCT03651895

21 **SUMMARY AT A GLANCE**

22 Elevated airway glucose is associated with bacterial infection in chronic obstructive
23 pulmonary disease (COPD) exacerbations. We tested whether metformin, a drug used to
24 treat diabetes, reduced airway glucose in patients with COPD. Recruitment/retention
25 difficulties led to an underpowered study, which observed no difference between
26 metformin and placebo on airway glucose.

27

28 **ABSTRACT**

29 **Background and Objective**

30 Patients with COPD have elevated levels of airway glucose. This may increase the risk of
31 bacterial infection leading to exacerbation and disease progression. We aimed to test
32 whether treating COPD patients with metformin, an oral hypoglycaemic used in diabetes,
33 reduced airway glucose.

34

35 **Methods**

36 In this randomized, double-blind, placebo-controlled crossover pilot study, we assigned
37 patients with COPD to two 3-month periods of treatment with 1g metformin or placebo
38 twice daily, followed by the alternate treatment after a 2-week washout period. Patients
39 were required to be free of infection, antibiotic or oral steroid treatment in the 8 weeks
40 prior to enrolment. The following were collected at baseline and monthly thereafter:
41 sputum (lower airways sample), nasal/upper airway lining fluid samples using synthetic
42 absorptive matrix (SAM), spirometry, and St Georges Respiratory Questionnaire (SGRQ) and
43 COPD Assessment Test (CAT) scores. The primary outcome was a change in sputum glucose
44 following 3 months treatment with metformin compared to 3 months of placebo.

45

46 **Results**

47 14 patients were randomised of whom 3 completed the study, mainly due to withdrawals
48 for exacerbations (8/11 withdrawals). In the n=4 patients who completed 3 months
49 metformin treatment, there were no significant changes in sputum or nasal glucose
50 compared to baseline. Metformin did not affect COPD symptom scores or spirometry.

51

52 **Conclusions**

53 Treatment with metformin in this underpowered pilot study did not significantly reduce
54 airway glucose in COPD. Larger studies are required to definitively evaluate this.

55

56 **Short title:**

57 Metformin and Airway Glucose in COPD

58

59 **Keywords:**

60 Chronic Obstructive Pulmonary Disease, COPD, Exacerbations, Metformin, Glucose,
61 Randomized Controlled Trial

63 INTRODUCTION

64

65 Chronic obstructive pulmonary disease (COPD) affects an estimated 400 million people
66 globally.⁽¹⁾ As well as chronic respiratory symptoms, patients with COPD suffer from
67 episodes of acutely increased symptoms called exacerbations. These can be triggered by
68 viral infections, bacterial infections and pollution, with bacteria detected in 50-60% of
69 exacerbations. Bacterial infection of the lower airways is also associated with airway
70 inflammation, disease progression and mortality.⁽²⁾ Exacerbations with bacterial infection
71 may require antibiotics, yet with antibiotic resistance a growing problem, there is a need for
72 alternative treatments. One therapeutic target is airway glucose; increased glucose levels
73 have been observed in the nasal lavage and sputum of stable COPD patients with further
74 increases during viral/bacterial COPD exacerbations.⁽³⁾ In primary human airway epithelia
75 models, lower levels of airway glucose impaired *Pseudomonas aeruginosa* growth in vitro.⁽⁴⁾
76 Furthermore, in mice, hyperglycaemia promoted *P. aeruginosa* and *Staphylococcus aureus*
77 growth in the airways.^(4, 5) This suggests that levels of airway glucose affect microorganism
78 growth and survival. It may also explain why human bronchial epithelial cells increase
79 glucose uptake in the presence of cytokines or pro-inflammatory mediators; the
80 subsequently reduced airway glucose levels may prevent infection.⁽⁶⁾

81

82 A potential approach to modulating airway glucose is with existing oral hypoglycaemic drugs,
83 developed and licensed for the treatment of diabetes. Metformin is one such drug and has
84 been safely used in patients with COPD and diabetes without causing hypoglycaemia.⁽⁷⁾ In
85 patients with co-morbid COPD and diabetes, metformin treatment is associated with a
86 lower risk of COPD-related hospitalisation and death, particularly after 2 years use, and

87 more so than other hypoglycaemic agents including insulin.⁽⁸⁻¹¹⁾ A 24% reduced risk of COPD
88 exacerbation has been reported following up to 180 days metformin use⁽¹²⁾ as well as a 28%
89 and 37% reduced risk of inpatient visits with COPD after 91-180 days or 181-365 days
90 metformin use respectively.⁽¹³⁾

91
92 The mechanism by which metformin reduces COPD exacerbations remains unclear. One
93 study found that 6 months of metformin treatment did not improve spirometry or alter
94 exhaled nitric oxide, despite being associated with significant changes in symptom scores.⁽¹⁴⁾
95 Furthermore, few studies have examined the effects of metformin in COPD patients without
96 diabetes. 1 month of treatment with metformin in patients with COPD admitted for an
97 exacerbation who did not have diabetes, had no impact on blood glucose (which was
98 modestly raised in both the metformin and placebo-treated groups), blood levels of the
99 inflammatory marker C-reactive protein, or scores on the COPD Assessment Test (CAT) or
100 Exacerbations of Chronic Pulmonary Disease Tool (EXACT).⁽¹⁵⁾ However treatment began at
101 hospital presentation, some days after viral infection and symptom onset, and blood but not
102 airway glucose levels were measured. We therefore undertook a pilot trial to determine
103 whether metformin altered airway glucose in COPD and to assess the feasibility of
104 conducting a full-scale trial of the efficacy of metformin prophylaxis in reducing COPD
105 exacerbations.

107 **METHODS**

108

109 **Human/Animal Ethics Approval Declaration:**

110 IRAS Number: 247421

111 Westminster Research Ethics Committee reference: 19/LO/0633

112

113 **Study Design**

114 The Metformin and Airway Glucose In COPD (MAGIC) trial was a double-blinded,
115 randomised, placebo-controlled cross-over trial in COPD. Recruitment began 17 May 2022
116 and ended 01 June 2023. Participants were randomised to metformin or placebo for 3
117 months, followed by a 2-week washout period before crossing over treatment arms. The
118 participants attended a baseline visit followed by monthly visits until the third month of
119 treatment was completed. This was repeated after crossing over. At these visits, symptoms,
120 quality of life (QOL) and spirometry were assessed, and sputum and nasal synthetic
121 absorptive matrix (SAMs) samples collected.

122

123 **Participants**

124 Patients aged 40-85 years with a clinical diagnosis of COPD confirmed on spirometry (post-
125 bronchodilator $FEV_1/FVC < 70\%$) and a smoking history of at least 15 pack years were eligible
126 for the study. Exclusion criteria included a diagnosis of diabetes (previously or on screening
127 bloods), treatment with metformin, contraindications to metformin (e.g. previous allergic
128 reaction to metformin, body mass index $< 18.5 \text{ kg/m}^2$), and a history of infection, antibiotic
129 and/or oral corticosteroid use in the previous 8 weeks. See supplementary material for full
130 inclusion and exclusion criteria. Written consent was obtained prior to participation.

131

132 **Intervention, Randomisation and Masking**

133 The study drugs were supplied by Sharp Clinical Services (Powys, UK), who produced visually
134 identical metformin and placebo tablets with the same packaging, differentiated only by a
135 unique pack ID. Eligible subjects were randomly assigned to either metformin or placebo
136 twice daily in a 1:1 ratio, according to a sequential randomisation list generated by a
137 statistician working independently of the trial that was encoded in the study database and
138 concealed up to allocation. Subjects and study investigators were blinded to treatment
139 allocation from randomisation until database lock. Treatment identity was concealed by
140 using placebo identical in packaging, labelling, schedule of administration, appearance, taste
141 and odour to metformin. Metformin was dosed at 500mg twice daily for one week to check
142 tolerability, increasing to 1g twice daily thereafter for the remainder of the 3 months.
143 Patients were considered compliant if $\geq 80\%$ of investigational medicinal product (IMP) was
144 taken.

145

146 **Outcomes**

147 The primary outcome was change in sputum glucose following 3 months' treatment with
148 metformin. Glucose was measured from sputum plugs using a commercial assay, the
149 Amplex Red Glucose Assay Kit (Thermo Fisher Scientific, UK). Secondary outcomes included
150 glucose concentrations in nasal SAM strips, COPD Assessment Test (CAT) and St George's
151 Respiratory Questionnaire (SGRQ) scores, and forced expiratory volume in 1 second (FEV₁).

152

153 **Statistical Analysis**

154 A sample size calculation indicated that 30 subjects were required to detect a reduction of
155 30% in airway glucose, based on the observation of similar reductions in airway glucose
156 following metformin treatment in mice,⁽¹⁶⁾ at 90% power using a two-sided test at the 5%
157 significance level. This was grossed up to 40 subjects to account for withdrawals.

158

159 Data were analysed using GraphPad Prism 9 (GraphPad Software, USA). Continuous
160 variables are presented as medians and interquartile ranges, with the Mann-Whitney U test
161 used to analyse between groups and Wilcoxon signed-rank test for paired analyses.

162 Differences were considered statistically significant at $p < 0.05$. All p values are two sided.

164 **RESULTS**

165

166 Between 17 May 2022 and 01 June 2023, 14 participants were enrolled. 11 were
167 subsequently withdrawn spread evenly across the metformin and placebo treatment arms,
168 8 due to lower respiratory tract infections (Figure 1A). 3 subjects completed 3 months of
169 both metformin and placebo; 8 volunteers completed 3 months of a single arm (4 per arm;
170 Figure 1B). In total, there were 16 sets of samples following 1 month's treatment of either
171 placebo or metformin (8 and 8 respectively); 12 from subjects who completed 1 month in
172 the study and a further 4 from subjects who crossed over and completed 1 month in the
173 other treatment arm). The trial was ended following expiry of the study drug on 31 May
174 2023.

175

176 **Figure 1. Outline of participation in MAGIC study.** Consort diagram (A). Timelines of
177 individual participants of study (B).

178

179 There was no significant change in the primary outcome, sputum glucose following 3
180 months treatment with metformin (median sputum glucose 68.92 (IQR 16.3 to 131.1) μM ,
181 either compared to baseline 5.3 (IQR 0.02 to 18) μM ($p=0.13$; $n=3$) or 3 months placebo
182 (median sputum glucose 12.2 (IQR 10 to 13) μM . Furthermore, there was no change in
183 sputum or nasal glucose with metformin treatment at any timepoint from baseline to 3
184 months (Figures 2A-B), including when only analysing patients who completed 3 months of
185 either arm of treatment (Figures 2C-D). We then analysed the change in sputum and nasal

186 glucose after 1 month's treatment compared to baseline and found no significant change
187 (Figures 2E-F).

188

189 **Figure 2. Effect of metformin on glucose in upper and lower airways.** Volunteers with
190 COPD were assigned to either active or placebo with a washout period before switching.
191 Glucose levels were measured in sputum (A, C, E) samples and synthetic absorptive matrices
192 (SAM) collected from the nose (B, D, F). Glucose levels over the time course of the study for
193 all participants measured (A, B); levels in individuals who complete a full 3-month
194 participation (C, D). Comparison of glucose levels at baseline (V1/V5) and one month later
195 (V2/ V6). At baseline N=9 participants in active, N=10 in placebo, n=4 participants finished a
196 3-month course of either metformin or placebo. Symbols represent individual participants
197 and lines medians. Statistical analysis was performed by Mann-Whitney test (A-D) and
198 Wilcoxon signed-rank test (E, F).

199

200

201 We additionally evaluated whether metformin affected airway function or symptoms of
202 COPD, assessed by the CAT and SGRQ questionnaires. There were no significant differences
203 in any measurement at baseline between the two arms (Figure 3A), and no difference after
204 1 month of treatment compared to baseline or between placebo and metformin treatment
205 (Figures 3B-F).

206

207 **Figure 3. Metformin had no impact on measures of airway function at one month.**

208 Volunteers with COPD were assigned to either active or placebo with a washout period
209 before switching. Measurements of airway function and symptoms were taken at visit 1 (A).
210 Airway function and symptoms were compared between initial visit 1 (V1) and Visit 2 (V2) of
211 each arm for FEV1 (B), FVC (C), PEF (D), CAT (E) and SGRQ (F). $n \geq 9$. Symbols represent
212 individual participants and lines medians. Statistical analysis was performed by Wilcoxon
213 signed-rank test.

214

215

216 **DISCUSSION**

217

218 This pilot study adds to the literature on metformin in COPD by showing for the first time
219 that up to 3 months of metformin treatment does not affect glucose levels in upper (nasal)
220 or lower (sputum) airways samples, albeit in small numbers of patients. If born out in larger
221 prospective studies, this would suggest that metformin does not reduce COPD
222 exacerbations by modulating airway glucose. It may be that metformin does not reduce
223 exacerbations at all; the reduced rate of COPD exacerbations seen in patients with comorbid
224 diabetes on metformin⁽⁸⁻¹¹⁾ is currently an association and not known to be causal.

225 Furthermore, a comparison of airway glucose in patients with only COPD not on metformin
226 against those with COPD and type II diabetes on metformin has not been made. Like other
227 studies, we failed to see any impact of metformin on FEV₁ or FVC,^(14, 17) even though high
228 airway glucose levels are associated with airway hyperresponsiveness.⁽¹⁸⁾

229 The main limitation of our study is the small sample size, due to a combination of under-
230 recruitment and a high number of withdrawals. Study recruitment was delayed due to the

231 COVID-19 pandemic and limited by the expiry date of the IMP when the study resumed,
232 hence only 14 out of a target 40 patients were recruited. We subsequently had a high drop-
233 out rate owing primarily to the exclusion of patients who developed a lower respiratory
234 tract infection (8 of the 11 withdrawals). These were excluded on the basis that both lower
235 respiratory tract infections and the oral steroids often used to treat them (alongside
236 antibiotics) are known to alter airways glucose and could therefore confound the results.
237 The inevitable consequence, however, in a population of patients who suffer frequent
238 exacerbations (particularly in the autumn and winter when most of the subjects were
239 enrolled) was a high number of withdrawals. Future studies could consider including these
240 participants and performing subgroup analyses on samples from non-infective timepoints.
241 However, even with our small numbers, there was no trend towards a difference in airway
242 glucose with metformin treatment.

243 The sputum results may have been affected by the poor quality of samples with low cell
244 counts and high cell death, likely due to immediate freezing of samples after collection. The
245 same would not be applicable to the nasal SAM samples, although these may not reflect
246 sputum (lower airways) glucose as differences have previously been observed in the
247 biochemicals measured in sputum and nasal SAM samples collected at the same time.⁽¹⁹⁾

248 Outcomes of previous studies have suggested that longer periods of treatments such as 6
249 months may be required to detect statistically significant changes in patient symptoms.⁽¹⁴⁾
250 At a minimum, 91 days of oral anti-hyperglycaemic treatment has been required to reduce
251 the risk of exacerbation, although this will be affected by the frequency of exacerbations.⁽¹³⁾
252 However exacerbations are relatively infrequent events and for this reason we chose a
253 mechanistic outcome, airway glucose, that should change sooner. Nonetheless future

254 research may want to investigate levels of airway glucose in patients with COPD and
255 comorbid diabetes treated with metformin for various durations, to those with COPD but
256 without diabetes. Similarly, a trial of an oral hypoglycaemic intervention might consider
257 studying a longer duration of treatment.

258 In summary, in this underpowered pilot study we found no effect of up to 3 months
259 metformin treatment on upper or lower airways glucose in COPD. Given the strong
260 epidemiological evidence linking metformin treatment to reduced rates of COPD
261 exacerbation and the growing problem of antibiotic resistance, larger interventional studies
262 of metformin treatment in COPD are warranted, and would ideally include analysis of a
263 possible mechanism (e.g. measurement of airways glucose).

265 **Author Contributions**

266 EF: Investigation, Writing - Original Draft; IF: Investigation; MRE: Supervision; TK:
267 Investigation; PM: Conceptualization, Funding acquisition; JST: Conceptualization, Funding
268 acquisition, Writing - Original Draft; SLJ: Supervision, Conceptualization, Funding acquisition,
269 Writing - Review & Editing; HF: Supervision, Investigation, Writing - Review & Editing.

270

271 **Acknowledgements:**

272 NIHR Imperial Biomedical Research Centre (BRC) (P74536)

273

274 **Conflict of Interest:** SLJ is a shareholder and Director of Virtus Respiratory Research Ltd.

275

276 **Data Availability Statement:** Data availability on request.

277

279 **REFERENCES**

280

281 1. Adeloje D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I, et al. Global, regional, and
282 national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in
283 2019: a systematic review and modelling analysis. *Lancet Respir Med*. 2022;10(5):447-58.

284 2. Beasley V, Joshi PV, Singanayagam A, Molyneaux PL, Johnston SL, Mallia P. Lung
285 microbiology and exacerbations in COPD. *Int J Chron Obstruct Pulmon Dis*. 2012;7:555-69.

286 3. Mallia P, Webber J, Gill SK, Trujillo-Torralbo MB, Calderazzo MA, Finney L, et al. Role
287 of airway glucose in bacterial infections in patients with chronic obstructive pulmonary
288 disease. *J Allergy Clin Immunol*. 2018;142(3):815-23 e6.

289 4. Pezzulo AA, Gutierrez J, Duschner KS, McConnell KS, Taft PJ, Ernst SE, et al. Glucose
290 depletion in the airway surface liquid is essential for sterility of the airways. *PLoS One*.
291 2011;6(1):e16166.

292 5. Garnett JP, Baker EH, Naik S, Lindsay JA, Knight GM, Gill S, et al. Metformin reduces
293 airway glucose permeability and hyperglycaemia-induced *Staphylococcus aureus* load
294 independently of effects on blood glucose. *Thorax*. 2013;68(9):835-45.


295 6. Garnett JP, Nguyen TT, Moffatt JD, Pelham ER, Kalsi KK, Baker EH, et al.
296 Proinflammatory mediators disrupt glucose homeostasis in airway surface liquid. *J Immunol*.
297 2012;189(1):373-80.

298 7. Hitchings AW, Archer JR, Srivastava SA, Baker EH. Safety of metformin in patients
299 with chronic obstructive pulmonary disease and type 2 diabetes mellitus. *COPD*.
300 2015;12(2):126-31.

- 301 8. Ho TW, Huang CT, Tsai YJ, Lien AS, Lai F, Yu CJ. Metformin use mitigates the adverse
302 prognostic effect of diabetes mellitus in chronic obstructive pulmonary disease. *Respir Res.*
303 2019;20(1):69.
- 304 9. Liang Z, Yang M, Xu C, Zeng R, Dong L. Effects and safety of metformin in patients
305 with concurrent diabetes mellitus and chronic obstructive pulmonary disease: a systematic
306 review and meta-analysis. *Endocr Connect.* 2022;11(9).
- 307 10. Bishwakarma R, Lin Y, Kuo Y, Sharma G. Metformin and Health Care Utilization in
308 Patients With Coexisting COPD and Diabetes. *Chest Journal.* 2016;150(4).
- 309 11. Bishwakarma R, Zhang W, Lin YL, Kuo YF, Cardenas VJ, Sharma G. Metformin use and
310 health care utilization in patients with coexisting chronic obstructive pulmonary disease and
311 diabetes mellitus. *Int J Chron Obstruct Pulmon Dis.* 2018;13:793-800.
- 312 12. P.L. T, Valencia-Hernandez C, Farne H, Bloom C. Effect of metformin on reducing the
313 risk of COPD exacerbations: a UK nested case-control study. *Thorax.* 2023;78.
- 314 13. Wang MT, Lai JH, Huang YL, Kuo FC, Wang YH, Tsai CL, et al. Use of antidiabetic
315 medications and risk of chronic obstructive pulmonary disease exacerbation requiring
316 hospitalization: a disease risk score-matched nested case-control study. *Respir Res.*
317 2020;21(1):319.
- 318 14. Sexton P, Metcalf P, Kolbe J. Respiratory effects of insulin sensitisation with
319 metformin: a prospective observational study. *COPD.* 2014;11(2):133-42.
- 320 15. Hitchings AW, Lai D, Jones PW, Baker EH, Metformin in CTT. Metformin in severe
321 exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial.
322 *Thorax.* 2016;71(7):587-93.
- 323 16. Gill SK, Hui K, Farne H, Garnett JP, Baines DL, Moore LSP, et al. Increased airway
324 glucose increases airway bacterial load in hyperglycaemia. *Sci Rep.* 2016;6:27636.

- 325 17. Kahnert K, Andreas S, Kellerer C, Lutter JI, Lucke T, Yildirim O, et al. Reduced decline
326 of lung diffusing capacity in COPD patients with diabetes and metformin treatment. *Sci Rep.*
327 2022;12(1):1435.
- 328 18. Cazzola M, Calzetta L, Rogliani P, Lauro D, Novelli L, Page CP, et al. High glucose
329 enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. *Am*
330 *J Respir Cell Mol Biol.* 2012;47(4):509-16.
- 331 19. Farne H, Groves HT, Gill SK, Stokes I, McCulloch S, Karoly E, et al. Comparative
332 Metabolomic Sampling of Upper and Lower Airways by Four Different Methods to Identify
333 Biochemicals That May Support Bacterial Growth. *Front Cell Infect Microbiol.* 2018;8:432.
334

A



medRxiv preprint doi: <https://doi.org/10.1101/2024.11.13.24317228>; this version posted November 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

B

Participant	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8
A	Active/Metformin	Active/Metformin						
B	Passive/Placebo	Passive/Placebo	Passive/Placebo	Passive/Placebo				
C	Active/Metformin	Active/Metformin	Active/Metformin	Active/Metformin	Active/Metformin	Active/Metformin		
D	Active/Metformin	Active/Metformin	Active/Metformin	Active/Metformin	Active/Metformin	Active/Metformin	Active/Metformin	Active/Metformin
E	Active/Metformin	Active/Metformin	Active/Metformin	Active/Metformin	Active/Metformin	Active/Metformin	Active/Metformin	Active/Metformin
F	Passive/Placebo	Passive/Placebo	Passive/Placebo	Passive/Placebo				
G	Active/Metformin							
H	Active/Metformin	Active/Metformin	Active/Metformin	Active/Metformin	Active/Metformin	Active/Metformin	Active/Metformin	Active/Metformin
I	Passive/Placebo	Passive/Placebo	Passive/Placebo	Passive/Placebo	Active/Metformin	Active/Metformin	Active/Metformin	Active/Metformin
J	Active/Metformin	Active/Metformin	Active/Metformin	Active/Metformin				
K	Passive/Placebo	Passive/Placebo	Passive/Placebo	Passive/Placebo				
L	Active/Metformin	Active/Metformin	Active/Metformin	Active/Metformin	Passive/Placebo	Passive/Placebo	Passive/Placebo	Passive/Placebo
M	Active/Metformin	Active/Metformin	Active/Metformin	Active/Metformin	Passive/Placebo	Passive/Placebo	Passive/Placebo	Passive/Placebo
N	Passive/Placebo	Passive/Placebo	Passive/Placebo	Passive/Placebo				

Active/Metformin

Passive/Placebo

Figure 1. Outline of participation in MAGIC study. Consort diagram (A). Timelines of individual participants of study (B).




Figure 2. Effect of metformin on glucose in Upper and lower airways. Volunteers with COPD were assigned to either active or placebo with a washout period before switching. Glucose levels were measured in sputum (A, C, E) samples and synthetic absorptive matrices (SAM) collected from the nose (B, D, F). Glucose levels over the time course of the study for all participants measured (A, B); levels in individuals who complete a full 3-month participation (C, D). Comparison of glucose levels at baseline (V1/V5) and one month later (V2/V6). At baseline N=9 participants in active, N=10 in placebo, n=4 participants finished a 3-month course of either metformin or placebo. Symbols represent individual participants and lines medians. Statistical analysis was performed by Mann-Whitney test (A-D) and Wilcoxon signed-rank test (E, F).




Figure 3. Metformin had no impact on measures of airway function at one month. Volunteers with COPD were assigned to either active or placebo with a washout period before switching. Measurements of airway function and symptoms were taken at visit 1 (A). Airway function and symptoms were compared between initial visit 1 (V1) and Visit 2 (V2) of each arm for FEV1 (B), FVC (C), PEF (D), CAT (E) and SGRQ (F). $n \geq 9$. Symbols represent individual participants and lines medians. Statistical analysis was performed by Wilcoxon signed-rank test.